Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary The U.S. administration has threatened tariffs of up to 200% on imported generic drugs. Branded medicines have seen limited impact so far. In part, that is because 17 drugmakers
Summary GSK will discontinue camlipixant, the chronic cough treatment it gained through its acquisition of Bellus Health. Two pivotal trials produced conflicting results. One dose worked in one study and
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Summary Zymeworks agreed to acquire Theravance Biopharma for $929 million, following the failure of ampreloxetine in neurogenic orthostatic hypotension. Consequently, Theravance entered a strategic review that identified its approved portfolio
Summary Ipsen announced the acquisition of Swiss biotech Memo Therapeutics on July 1, 2026. The deal is valued at up to $800 million, with €200 million upfront and more than
Summary Tennessee enacted the FAIR Rx Act, banning pharmacy benefit manager-owned pharmacies from operating in the state. Express Scripts and the PCMA filed separate lawsuits in June 2026 to block
Summary A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and Bristol Myers Squibb’s Opdivo Qvantig — subcutaneous versions of established
On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for
Summary Contingent value rights (CVRs) — conditional payments tied to regulatory approval, reimbursement milestones, or sales thresholds — have become standard practice in pharma and biotech acquisitions, with their use
Why CVRs Are Becoming the Quiet Engine Behind Today’s Biotech Deals The biotech sector is navigating one of the most complex market environments in recent memory. Volatile valuations, cautious capital,